Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Carrascosa

Showing results (1-10 of 232) with videos related to

Pageof 24
Sort By:
Actas Dermo-Sifiliograficas|September 7, 2015
[Phototherapy for the management of chronic graft-vs-host disease]J M Carrascosa
Actas Dermo-Sifiliograficas|December 17, 2008
[Strategies to improve treatment with efalizumab]J M Carrascosa
Actas Dermo-Sifiliograficas|March 10, 2009
[Reality, perspectives, and uncertainty in narrow-band UVB therapy for psoriasis]J M Carrascosa
Actas Dermo-Sifiliograficas|April 30, 2013
Immunogenicity in biologic therapy: implications for dermatologyJ M Carrascosa
Actas Dermo-Sifiliograficas|May 18, 2007
[Should benign and trivial cutaneous lesions be treated in the Public Health System?]J M Carrascosa
Actas Dermo-Sifiliograficas|March 26, 2014
Sun protection in children: realities and challengesY Gilaberte, J M Carrascosa
Actas Dermo-Sifiliograficas|September 1, 2007
[Normal cutaneous flora and secondary bacterial infection]X Soria, J M Carrascosa
Actas Dermo-Sifiliograficas|June 3, 2014
Drug survival in biologic therapy. Do we know what it means? Can we calculate it?J M Carrascosa, J Notario
Actas Dermo-Sifiliograficas|May 25, 2010
[Transition of classical systemic treatments to etanercept]C Ferrándiz, J M Carrascosa
The British Journal of Dermatology|March 21, 2007
Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish instituteC Ferrándiz, J M Carrascosa
Pageof 24

Showing results (1-10 of 232) with videos related to

Sort By:
Pageof 24
Actas Dermo-Sifiliograficas|September 7, 2015
[Phototherapy for the management of chronic graft-vs-host disease]J M Carrascosa
Actas Dermo-Sifiliograficas|December 17, 2008
[Strategies to improve treatment with efalizumab]J M Carrascosa
Actas Dermo-Sifiliograficas|March 10, 2009
[Reality, perspectives, and uncertainty in narrow-band UVB therapy for psoriasis]J M Carrascosa
Actas Dermo-Sifiliograficas|April 30, 2013
Immunogenicity in biologic therapy: implications for dermatologyJ M Carrascosa
Actas Dermo-Sifiliograficas|May 18, 2007
[Should benign and trivial cutaneous lesions be treated in the Public Health System?]J M Carrascosa
Actas Dermo-Sifiliograficas|March 26, 2014
Sun protection in children: realities and challengesY Gilaberte, J M Carrascosa
Actas Dermo-Sifiliograficas|September 1, 2007
[Normal cutaneous flora and secondary bacterial infection]X Soria, J M Carrascosa
Actas Dermo-Sifiliograficas|June 3, 2014
Drug survival in biologic therapy. Do we know what it means? Can we calculate it?J M Carrascosa, J Notario
Actas Dermo-Sifiliograficas|May 25, 2010
[Transition of classical systemic treatments to etanercept]C Ferrándiz, J M Carrascosa
The British Journal of Dermatology|March 21, 2007
Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish instituteC Ferrándiz, J M Carrascosa
Pageof 24